This ASCENT-03 Phase 3 study compared sacituzumab govitecan with chemotherapy in patients with previously untreated advanced TNBC who are ineligible for PD-L1 inhibitors, demonstrating potential efficacy and safety in this challenging population. Read More ›

This phase 1/2 trial presents the first clinical data on DB-1305/BNT325, a TROP2-targeting antibody–drug conjugate, demonstrating efficacy and safety in patients with pretreated triple-negative breast cancer. Read More ›

The phase 3 ASCENT-04/KEYNOTE-D19 trial evaluated patient-reported outcomes comparing sacituzumab govitecan plus pembrolizumab with chemotherapy plus pembrolizumab in previously untreated PD-L1–positive metastatic TNBC, offering insights into quality of life and symptom management. Read More ›

This trial evaluated the addition of low-dose pembrolizumab to neoadjuvant anthracycline and taxane regimens, revealing potential synergy in triple-negative breast cancer. Read More ›

This study highlights the remarkable antitumor potency of a novel MUC1-C ADC, offering a promising therapeutic option for patients with triple-negative breast cancer. Read More ›

The combination of BEBT-209 with gemcitabine and carboplatin showed promising efficacy and a tolerable safety profile in metastatic triple-negative breast cancer (TNBC). Read More ›

Sacituzumab govitecan and pembrolizumab combination therapy showed promising clinical benefit in early-stage triple-negative breast cancer (TNBC). Read More ›

The combination of camrelizumab, apatinib, and chemotherapy shows favorable outcomes in the neoadjuvant setting for stage II-III triple-negative breast cancer (TNBC), particularly in patients with programmed death-ligand 1 positivity. Read More ›

The combination of benmelstobart and anlotinib showed a numerical, though not a statistically significant improvement in progression-free survival and overall survival over nab-paclitaxel in recurrent or metastatic triple-negative breast cancer (TNBC). Read More ›

The ASCENT-04/KEYNOTE-D19 trial highlights sacituzumab govitecan plus pembrolizumab as a promising first-line therapy for patients with programmed death-ligand 1 (PD-L1)-positive, advanced triple-negative breast cancer (TNBC). Read More ›